This rise in prescribing of prescription opioids in the last 2 decades of the 20th century occurred at a time during which medical professionals were urged to resort to prescription opioids to manage untreated and chronic noncancer pain.
If physicians have a genuine interest in acting with beneficence and nonmaleficence, they should recognize that their prescribing habits have significant consequences for their patients.
Increasing evidence supports the notion that an individual’s specific response to pain or pain treatments may be affected by particular gene polymorphisms.
An interview with Penney Cowan, founder and chief executive officer of the American Chronic Pain Association, where she discusses the ACPA’s publication aimed at helping healthcare practitioners improve care of patients with chronic pain.
Intravenous administration of acetaminophen (APAP) may be less effective than oral administration of APAP for reducing opioid use after total hip or knee arthroplasty.
Implementation of the U.S. Centers for Disease Control and Prevention opioid prescribing recommendations should be consistent with the guideline’s intent.
The U.S. Food and Drug Administration is launching on April 25, 2019, its “Remove the Risk” campaign, aimed at promoting the safe disposal of unused opioids.
Physical activity-adjusted pain measures may be associated with the severity of radiographic knee osteoarthritis, and be helpful for the assessment of functional capacity in these patients.
Researchers examined pain intensity ratings in veterans with OA to determine if changes in published analgesic policies and initiatives affect patient outcomes.
Researchers examined the prevalence and distribution of clinical and ultrasound pathologic findings at ankle level in patients with rheumatoid arthritis.
The program did not significantly reduce pain, but did improve key measures of pain coping and perceived ability to manage pain in African American patients with osteoarthritis.
